23Better Future for Today’s Children and for All Generations to ComeSummary of ActivityWe are developing genetically modified T-cells to express a chimeric antigen re-ceptor (CAR) redirected to tumor antigens. Cancer immunotherapy using CAR T cells has been applied in the treatment of acute lymphoblastic leukemia and ma-lignant lymphoma. We are developing a new CAR-T cells to treat acute myeloid leukemia or pediatric solid tumors. We are also working on a new cancer gene therapy using a biodegradable liposome (nanocapsule). We aim to deliver genes of interest into the target cancer cells using the nanocapule to improve safety and reduce the costs of gene therapy.・Cancer immunotherapy with CAR-T cells・Cancer gene therapy with biodegradable liposome (nanocapsule)We strive to improve medical care for children and all future generations by understanding the mechanisms of disease, developing potential treatments, and gathering evidence from daily clinical practice. Your research discoveries may generate a cure for some disease!Because our department has various areas of subspecialties, graduates can gain a lot of knowledge from the doctors in each division. Graduates also integrate data from multiple sources to identify patient condition, thereby deepening their critical and creative thinking abilities as a physician and a researcher.Research subjectOutlook for researchOutlook for students after graduationPediatrics（Chief: Prof. & Chair : Yozo Nakazawa）Chimeric Antigen Receptor (CAR) T-cell Therapy We use our original “non-viral T-cell culture method” for gene engineering. This meth-od is highly and widely appreciated for its simplicity and low cost.Cancer Gene Therapy with biodegradable liposome (nanocapsule) We are also devel-oping a drug delivery system to therapeutic gene into cancer cellsChallenging for next generation of melanoma treatmentSummary of ActivityOur main projects are the diagnostic method, evaluation method of disease status and new treatment method of malignant melanoma. Because progressed melanoma is difficult to cure, early diagnosis and treatment are very important for patients. Sometimes, it is difficult to distinguish the early melanoma from the benign pigmented nevus. We aim to establish the new diagnosis methods using photographs and a noninvasive method using the nail pieces.Today, immune checkpoint inhibitors and molecular target therapy are often used for the patients suffered from progressed melanoma. We research availability of the combination therapy of ICBs and angiotensin II receptor locker (ARB).・Assessment for melanoma patients using liquid biopsy・Treatment of melanoma by combination of ICBs and ARB.・Imaging diagnosis for melanoma using RGB values・Noninvasive diagnosis by measurement melanin in the nails.Since malignant melanoma is one of the aggressive cancers, once it progress, complete re-mission is difficult. Even using immune checkpoint blockade, objective response rate is up to 30%. We hope that outcomes of our study contribute for improvement both of early diagnosis and treatment of advanced melanoma. You can continue the research in our laboratory or study abroad. Because the our research themes are linked to medical treatment, the knowledge obtained in the research is often useful for clinical practice. There are some members in our laboratory who continue both the research and clinical practice after the graduationResearch subjectOutlook for researchOutlook for students after graduationDermatology（Chief: Prof. Ryuhei Okuyama）Graduate students actively experiment. We can use experimental equipments such as ow cytometry in our laboratory.We accept international students.We instruct politely.Nevus or Melanoma ? Can you diagnose ?
元のページ ../index.html#25